Huons Bio Pharma, Huons Group's botulinum toxin specialist, said on the 14th it appointed Executive Director Lee Jeong-hee (photo) as its new CEO.
Born in 1976, the new CEO Lee Jeong-hee earned an MBA from Aalto University in Finland (formerly the Helsinki School of Economics). Lee then spent more than 23 years at Ipsen Korea, Hanwha Pharmaceutical, Hugel, Daewoong Pharmaceutical, JETEMA, and CKD BiO, building expertise in marketing, sales, and strategic planning. While working at Hugel and Daewoong Pharmaceutical, Lee handled overseas business development and is credited with laying the foundation for global market entry.
In January, Huons Bio Pharma received product approval from China's National Medical Products Administration (NMPA) for 100 units of the botulinum toxin "Hutox (Hutox®, domestic name Liztox·LIZTOX®)" and began its first shipments last month.
Lee Jeong-hee said, "Huons Bio Pharma is at an important inflection point as it begins full-fledged exports to China with its botulinum toxin product," and added, "We will do our best for sustained growth, including expanding research and development for next-generation products."
Huons Bio Pharma currently sells its products in 16 countries, including Thailand and Russia. The company plans to expand global sales focused on South America, the Middle East, and Southeast Asia.